It is noteworthy that psoriasis clinical studies of ustekinumab [29], alefacept (CD2 binding portion LFA-3)[8], and etanercept (TNF-receptor fusion protein)[9] all showed greater decreases in CD3+ T cells compared to CD11c+ cells. This evidence concerns the gene CD58 and psoriasis.